3i, LP New York, NY 10005 Anson Investments Master Fund LP c/o Anson Advisors Inc. 155 University Ave., Suite 207 Toronto, ON Canada M5H3B7 Anson East Master Fund LP c/o Anson Advisors Inc. 155 University Ave., Suite 207 Toronto, ON Canada M5H3B7Senior Secured Convertible Notes Amendment • December 27th, 2021 • Ensysce Biosciences, Inc. • Pharmaceutical preparations • New York
Reference is made to (a) that certain Securities Purchase Agreement (as modified from time to time, the “Purchase Agreement”), dated as of September 24, 2021, between the Company and the purchasers identified therein, which are the same as the three addressees listed above (collectively, the “Investors”) and (b) the Senior Secured Convertible Promissory Notes (as modified from time to time, the “Senior Secured Convertible Notes”), and (c) and the other transaction documents, as modified from time to time, referred to collectively, as the “Transaction Documents”). Capitalized terms used but not defined herein shall have the meanings given to them in the Purchase Agreement, or if not defined therein, in the Notes, or if not defined therein, in the applicable Transaction Document, in each case as of the date hereof.
September 10, 2007Senior Secured Convertible Notes Amendment • September 12th, 2007 • Nutracea • Grain mill products
AMENDMENT TO SENIOR SECURED CONVERTIBLE NOTES DUE 2021Senior Secured Convertible Notes Amendment • June 30th, 2011 • Ap Pharma Inc /De/ • Pharmaceutical preparations
This AMENDMENT TO SENIOR SECURED CONVERTIBLE NOTES DUE 2021 (this “Amendment”) is entered into as of June 29, 2011, by and between A.P. Pharma, Inc., a Delaware corporation (the “Company”) and the Purchasers (defined below).
